These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12514703)

  • 1. Biotech meets NIH to discuss poor disease markets.
    Dove A
    Nat Med; 2003 Jan; 9(1):7. PubMed ID: 12514703
    [No Abstract]   [Full Text] [Related]  

  • 2. National Institutes of Health criticised for not preventing conflicts of interest.
    Tanne JH
    BMJ; 2004 Jul; 329(7456):10. PubMed ID: 15231595
    [No Abstract]   [Full Text] [Related]  

  • 3. "NIH-money-for-drug-patent-life" proposal rejected.
    Fox JL
    Nat Biotechnol; 1997 Dec; 15(13):1338. PubMed ID: 9415880
    [No Abstract]   [Full Text] [Related]  

  • 4. Public biotech 98: the numbers.
    Lähteenmäki R; Michael A; Marshall A
    Nat Biotechnol; 1999 May; 17(5):429-32. PubMed ID: 10331795
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative effectiveness casts first shadows across US industry.
    Waltz E
    Nat Biotechnol; 2009 Mar; 27(3):211-2. PubMed ID: 19270651
    [No Abstract]   [Full Text] [Related]  

  • 7. The Human Genome Project: a public good.
    Hudson K
    Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
    [No Abstract]   [Full Text] [Related]  

  • 8. Startups hope federal study fixes SBIR flaws.
    Basu P
    Nat Biotechnol; 2004 Jun; 22(6):644. PubMed ID: 15175671
    [No Abstract]   [Full Text] [Related]  

  • 9. Scientific commercialization. US biotech in good health.
    Gershon D
    Nature; 1991 Oct; 353(6347):785. PubMed ID: 1944544
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotech blockbusters consolidate markets.
    Lawrence S
    Nat Biotechnol; 2006 Dec; 24(12):1466. PubMed ID: 17160033
    [No Abstract]   [Full Text] [Related]  

  • 11. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NIH at the crossroads.
    Nature; 2003 Oct; 425(6958):545. PubMed ID: 14534548
    [No Abstract]   [Full Text] [Related]  

  • 13. Conflicts of interest at the NIH: no easy solution.
    Resnik DB
    Hastings Cent Rep; 2005; 35(1):18-20. PubMed ID: 15799496
    [No Abstract]   [Full Text] [Related]  

  • 14. Bush FY 2002 federal budget request vague.
    Fox JL
    Nat Biotechnol; 2001 Apr; 19(4):290. PubMed ID: 11283554
    [No Abstract]   [Full Text] [Related]  

  • 15. The NIH, research institutions and industry: working together on a shared goal.
    Omary MB
    Gastroenterology; 2007 May; 132(5):1647-50. PubMed ID: 17484859
    [No Abstract]   [Full Text] [Related]  

  • 16. Biomedical research. Feeling the heat, NIH tightens conflict-of-interest rules.
    Kaiser J
    Science; 2004 Jul; 305(5680):25-6. PubMed ID: 15232077
    [No Abstract]   [Full Text] [Related]  

  • 17. Conflicts at the NIH (cont.).
    Nature; 2004 Jul; 430(6995):1. PubMed ID: 15229563
    [No Abstract]   [Full Text] [Related]  

  • 18. Agency set up to tackle bioterror.
    Wadman M
    Nature; 2006 Dec; 444(7121):796-7. PubMed ID: 17167438
    [No Abstract]   [Full Text] [Related]  

  • 19. Pfizer-Pharmacia merger bodes ill for biotech?
    Fletcher L
    Nat Biotechnol; 2002 Sep; 20(9):857-8. PubMed ID: 12205489
    [No Abstract]   [Full Text] [Related]  

  • 20. NIH researchers face blanket consulting ban.
    Marris E
    Nature; 2004 Sep; 431(7008):497. PubMed ID: 15457226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.